Anti-MG7 CAR T cell therapy (Shanghai GeneChem)

N/A

Report date: 2024/12/23 13:28:02

Base Information

Drug NameAnti-MG7 CAR T cell therapy (Shanghai GeneChem)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMG7 antigen inhibitors
TargetsMG7 antigen
Therapy Area/IndicationsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Genechem Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Genechem Co Ltd
Active IndicationsN/A
Inactive IndicationsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A